Reuters: Health
The U.S. Food and Drug Administration on Monday declined to approve Lipocine Inc's oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer's shares down 34%.
FDA rejects Lipocine's testosterone drug for third time
FDA rejects Lipocine's testosterone drug for third time
Reuters: Health
The U.S. Food and Drug Administration on Monday declined to approve Lipocine Inc's oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer's shares down 34%.
Reuters: Health
The U.S. Food and Drug Administration on Monday declined to approve Lipocine Inc's oral drug to treat a condition that results in lower production of male sex hormone for the third time, sending the drug developer's shares down 34%.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment